Is ischemia modified albumin a good marker in acute exacerbation of chronic obstructive pulmonary disease?

Year 2020, Volume: 6 Issue: 5, 388 - 394, 04.09.2020

Nalan Ogan , Togay Evrin , Tuba Çandar , Aslıhan Alhan Meral Gülhan

https://doi.org/10.18621/eurj.517778

Abstract

Objectives:
Our
aim is to compare the Ischemia modified albumin (IMA) in patients with acute
exacerbation of Chronic Obstructive Pulmonary Disease (COPD) with a high
oxidative and inflammatory biologic marker like C-reactive protein (CRP) and to
investigate its employability in AECOPD and the relationship between arterial
blood gas and pulmonary function parameters.

Methods: Forty-six
patients diagnosed with acute exacerbation of COPD between March 2015 -
September 2016 at Ufuk University School of Medicine were included. The 1^st
and 5^th days of IMA and CRP levels were measured. Also, IMA levels
were given in absorbance units (ABSU).

Results: Total
46 patients of COPD, 13 (28.3%) were females and 33 (71.76%) were males. The
mean age of the patients was 71.39 ± 10.04 years. The 1^st and 5^th
day values of IMA, ABSU and CRP were 1.08 ± 0.33 and 0.49 ± 0.24; 1.06 ± 0.34
and 0.49 ± 0.26; and 29.25 (3.10-288.00) and 6.35 (0.30-149.00), respectively (p < 0.001). No significant
correlation was determined between IMA and CRP. Also, no correlation were
determined between the parameters of arterial blood gas and pulmonary function.

Conclusions: Although IMA values showed significant
increase during acute exacerbation of COPD and decreased after treatment, CRP
still appeared more effective in evaluating the exacerbation status and
following up of the treatment of patients with COPD. 

Keywords

Chronic obstructive pulmonary disease, exacerbation, C-reactive protein, ischemia modified albumin

References

• 1. 2019 Global Strategy for Prevention, Diagnosis and Management of COPD. Available at: https://goldcopd.org/gold-reports/. Accessed February 21, 2019.
• 2. Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. Int J Chron Obstruct Pulmon Dis 2011;6:413-21.
• 3. Rahman I, Morrison D, Donaldson K, MacNee W. Systemic oxidative stress in asthma, COPD, and smokers. Am J Respir Crit Care Med 1996;154:1055-60.
• 4. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007;370:786-96.
• 5. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:867-74.
• 6. Bar-Or D, Lau E, Winkler JV. A novel assay for cobalt-albumin binding and its potential as a marker for myocardial ischemia-a preliminary report. J Emerg Med 2000;19:311-5.
• 7. Hazini A, Cemek M, Isıldak I, Alpdagtaş S, Onul A, Senel U, et al. Investigation of ischemia modified albumin, oxidant and antioxidant markers in acute myocardial infarction. Postep Kardiol Inter 2015;11:298-303.
• 8. Nepal M, Jaisawal S, Guragain M, Kafle P, Mukkera S, Kumar R, et al. Ischemic modified albumin (IMA) as a novel marker for ischemic heart disease and surrogate marker for other high oxidative-ischemic conditions. J Cardiovasc Dis Res 2017;8:112-6.
• 9. Jena I, Nayak SR, Behera S, Singh B, Ray S, Jena D, et al. Evaluation of ischemia-modified albumin, oxidative stress, and antioxidant status in acute ischemic stroke patients J Nat Sci Biol Med 2017;8:110-3.
• 10. Guntas G, Sahin A, Duran S, Kahraman R, Duran I, Sonmez C, et al. Evaluation of Ischemia-Modified Albumin in Patients with Inflammatory Bowel Disease. Clin Lab 2017;63:341-7.
• 11. Kumar P, Subramanian K. The role of ischemia modified albumin as a biomarker in patients with chronic liver disease. J Clin Diagn Res 2016;10:9-12.
• 12. Ozben S, Huseyinoglu N, Hanikoglu F, Guvenc TS, Yildirim BZ, et al. Advanced oxidation protein products and ischaemia-modified albumin in obstructive sleep apnea. Eur J Clin Invest 2014;44:1045-52.
• 13. Turedi S, Gunduz A, Mentese A, Topbas M, Karahan SC, Yeniocak S, et al. The value of ischemia-modified albumin compared with d-dimer in the diagnosis of pulmonary embolism. Respir Res 2008;9:1-12.
• 14. Sharma R, Gaze DC, Pellerin D, Mehta RL, Gregson H, Streather CP, et al. Ischemia-modified albumin predicts mortality in ESRD. Am J Kidney Dis 2006;47:493-502.
• 15. Dominguez-Rodriguez A, Abreu-Gonzalez P, Jimenez-Sosa A, Samimi-Fard S, Idaira HB. Does ischemia-modified albumin add prognostic value to the thrombolysis in myocardial infarction risk score in patients with ST-segment elevation myocardial infarction treated with primary angioplasty? Biomarkers 2009;14:43-8.
• 16. Lippi G, Montagnana M, Salvagno GL, Guidi GC. Standardization of ischaemia-modified albumin testing: adjustment for serum albümin. Clin Chem Lab Med 2007;45:261–2.
• 17. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009;33:1165-85.
• 18. Barnes PJ, Shapiro SD, Pauwels RA. Chronic obstructive pulmonary disease: Molecular and cellular mechanisms. Eur Respir J 2003;22:672-88.
• 19. Can U, Yerlikaya FH, Yosunkaya S. Role of oxidative stress and serum lipid levels in stable chronic obstructive pulmonary disease. J Chin Med Assoc 2015;78:702-8.
• 20. Yang KY, Su VYF. Serum oxidative stress and chronic obstructive pulmonary disease. J Chin Med Assoc 2015;78:687-8.
• 21. Roy D, Quiles J, Gaze DC, Collinson P, Kaski JC, Baxter GF. Role of reactive oxygen species on the formation of the novel diagnostic marker ischaemia modified albumin. Heart 2006;92:113-4.
• 22. Paulraj S, Kumar PA, Subramaniam K, Karthikeyan R. Role of oxidative stress in COPD. Can we use a novel biomarker to measure it? J Dent Med Sci 2017;16:52-6.
• 23. Zapico-Muniz E, Santalo-Bel M, Merce-Muntanola J, Montiel JA, Martinez-Rubio A, Ordonez-Llanos J. Ischemia-modified albumin during skeletal muscle ischemia. Clin Chem 2004;50:1063-5.